Bayer Animal Health and Paraco agree on access to lead molecules
Bayer Animal Health GmbH and Paraco Technology Limited, a 100% owned subsidiary of AgResearch, New Zealand’s largest Crown Research Institute, announced they have signed an option agreement allowing Bayer exclusive access to Paraco’s current lead molecules for testing and development in animal health. The focus in the foreseen activities lies in the research of parasiticides.
Dr Peggy Dillender, Global Head of acquisitions and licensing at Bayer Animal Health, said that Bayer were pleased to sign the agreement with Paraco and to tap into some of the innovative animal health research being conducted in New Zealand. “We hope this will be the beginning of a long and fruitful relationship between Bayer, Paraco and indirectly AgResearch,” said Dr Dillender.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.